Cargando…

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions

Galcanezumab is a humanized monoclonal antibody blocking the calcitonin gene-related peptide (CGRP) pathway by targeting the CGRP. Data from four phase-3 randomized placebo-controlled clinical trials showed that galcanezumab is superior to placebo in reducing migraine headaches, migraine-specific qu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gklinos, Panagiotis, Mitsikostas, Dimos D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998387/ https://www.ncbi.nlm.nih.gov/pubmed/33803190 http://dx.doi.org/10.3390/ph14030245

Ejemplares similares

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
por: Gklinos, Panagiotis, et al.
Publicado: (2020)

Galcanezumab for migraine
Publicado: (2020)

New players in the preventive treatment of migraine
por: Mitsikostas, Dimos D., et al.
Publicado: (2015)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
por: Zhao, Xiuyuan, et al.
Publicado: (2020)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

Treating primary headaches – management of migraine
por: Mitsikostas, Dimos D
Publicado: (2013)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy
por: Lupi, Chiara, et al.
Publicado: (2019)

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
por: Kuruppu, Dulanji K., et al.
Publicado: (2021)

Correction to: Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
por: Zhao, Xiuyuan, et al.
Publicado: (2021)

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
por: Goadsby, Peter J, et al.
Publicado: (2019)

Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine
por: Vikelis, Michail, et al.
Publicado: (2012)

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
por: Igarashi, Hisaka, et al.
Publicado: (2021)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome
por: Deligianni, Christina, et al.
Publicado: (2023)

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
por: Bangs, Mark E., et al.
Publicado: (2020)

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
por: Detke, Holland C., et al.
Publicado: (2018)

Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
por: Rosen, Noah, et al.
Publicado: (2019)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
por: Takizawa, Tsubasa, et al.
Publicado: (2022)

Predictors of galcanezumab response in a real-world study of Korean patients with migraine
por: Kim, Seung Ae, et al.
Publicado: (2023)

Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
por: Bangs, Mark E., et al.
Publicado: (2020)

Neck pain in episodic migraine: premonitory symptom or part of the attack?
por: Lampl, Christian, et al.
Publicado: (2015)

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
por: Martinez, James M, et al.
Publicado: (2020)

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
por: Fofi, Luisa, et al.
Publicado: (2022)

Neurological manifestations of COVID-19: a review of what we know so far
por: Gklinos, Panagiotis
Publicado: (2020)

Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
por: Kuruppu, Dulanji K., et al.
Publicado: (2021)

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
por: Reuter, Uwe, et al.
Publicado: (2021)

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
por: Kielbasa, William, et al.
Publicado: (2019)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
por: Pellesi, Lanfranco, et al.
Publicado: (2020)

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
por: Ruff, D. D., et al.
Publicado: (2019)

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
por: Camporeale, Angelo, et al.
Publicado: (2018)

Galcanezumab for the Management of Migraine: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Abu-Zaid, Ahmed, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m549mhlf2abi1d5eooga5m5jtf